Although the down-regulation of A20 or CYLD has been reported in certain malignancies16,17, it has not been clarified whether the deregulation of expression of these negative regulators is involved in the persistent activation of the NF-κB pathway in ATLL. This evidence concerns the gene TNFAIP3 and adult T-cell leukemia/lymphoma.